AbbVie 3Q Global Humira Revenue $683M, Down 31.2% >ABBV

What happened

AbbVie reported third-quarter global Humira revenue of $683 million, a decline of 31.2% from the prior year, according to the supplied headline.

Confirmed

Global impact / market context

Humira is a major AbbVie medicine, so falling sales reduce revenue from an established product and can pressure profit if cost cuts and newer drugs do not offset the shortfall.

Analyst inference

The decline points to eroding Humira sales, likely from competition, which matters for AbbVie's revenue mix and for investors judging whether newer medicines can replace lost sales.

Analyst inference

What to watch

1. AbbVie's third-quarter global Humira revenue was $683 million, down 31.2%, a confirmed figure investors can compare with future quarterly results. Confirmed
2. Watch whether Humira declines continue at a similar pace, which would signal sustained pressure on AbbVie's revenue base. Analyst inference
3. Watch AbbVie's other medicines and cost base to see if they offset lost Humira revenue and protect profit per sale. Analyst inference

Evidence

• Original source link unavailable